Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA

Author： Karalis Vangelis   Symillides Mira   Macheras Panos  

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.29, Iss.4, 2012-04, pp. : 1066-1077

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of Bioequivalence for Highly Variable Drugs with Scaled Average Bioequivalence

By Tothfalusi Laszlo  

Clinical Pharmacokinetics, Vol. 48, Iss. 11, 2009-11 ,pp. : 725-743

Adis International

Access to resources Recommend Favorite

Innovative approaches for demonstration of bioequivalence: the US FDA perspective

By Zhang Xinyuan   Zheng Nan   Lionberger Robert A   Yu Lawrence X  

Therapeutic Delivery, Vol. 4, Iss. 6, 2013-06 ,pp. : 725-740

Future Science

Access to resources Recommend Favorite

Current regulatory approaches of bioequivalence testing

By Karalis Vangelis   Macheras Panos  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 8, 2012-08 ,pp. : 929-942

Informa Healthcare

Access to resources Recommend Favorite

Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards

By Lobenberg R.   Amidon G.L.  

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 50, Iss. 1, 2000-07 ,pp. : 3-12

Elsevier

Access to resources Recommend Favorite

US FDA regulatory news

By  

Inpharma, Vol. 1, Iss. 1271, 2001-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite